Alto Neuroscience Inc. ANRO
i
Market datapartial · fetched 2026-11-07T16:10:50.351Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:00:00.002848194Z
FundamentalsAlpha Vantage · unavailable
Alto Neuroscience Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 18.03 | 332.2% | 38.1% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 36.12 | 285.3% | 53.3% | 23.26 | 185.0% | 17.5% |
| 40Δ | 31.05 | 227.2% | 33.2% | 24.28 | 160.4% | 13.6% |
| 45Δ | 28.71 | 191.0% | 23.8% | 25.25 | 142.2% | 10.6% |
| 50Δ | 27.03 | 160.5% | 17.2% | 26.06 | 138.6% | 9.3% |
| 55Δ | 25.35 | 130.1% | 10.5% | 26.87 | 135.0% | 8.0% |
| 60Δ | 24.52 | 118.0% | 7.9% | 27.69 | 131.4% | 6.7% |
| 65Δ | 23.92 | 110.6% | 6.3% | 28.50 | 127.8% | 5.4% |
| 70Δ | 23.31 | 103.3% | 4.8% | 29.32 | 124.2% | 4.1% |
| 75Δ | 22.71 | 95.9% | 3.3% | 30.36 | 122.9% | 2.9% |
| 80Δ | 21.82 | 98.0% | 2.4% | 32.61 | 133.7% | 2.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.03
- IV
- 332.2%
- B/E move
- 38.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 36.12
- IV
- 285.3%
- B/E move
- 53.3%
- Pseudo strike
- 23.26
- IV
- 185.0%
- B/E move
- 17.5%
40Δ
- Pseudo strike
- 31.05
- IV
- 227.2%
- B/E move
- 33.2%
- Pseudo strike
- 24.28
- IV
- 160.4%
- B/E move
- 13.6%
45Δ
- Pseudo strike
- 28.71
- IV
- 191.0%
- B/E move
- 23.8%
- Pseudo strike
- 25.25
- IV
- 142.2%
- B/E move
- 10.6%
50Δ
- Pseudo strike
- 27.03
- IV
- 160.5%
- B/E move
- 17.2%
- Pseudo strike
- 26.06
- IV
- 138.6%
- B/E move
- 9.3%
55Δ
- Pseudo strike
- 25.35
- IV
- 130.1%
- B/E move
- 10.5%
- Pseudo strike
- 26.87
- IV
- 135.0%
- B/E move
- 8.0%
60Δ
- Pseudo strike
- 24.52
- IV
- 118.0%
- B/E move
- 7.9%
- Pseudo strike
- 27.69
- IV
- 131.4%
- B/E move
- 6.7%
65Δ
- Pseudo strike
- 23.92
- IV
- 110.6%
- B/E move
- 6.3%
- Pseudo strike
- 28.50
- IV
- 127.8%
- B/E move
- 5.4%
70Δ
- Pseudo strike
- 23.31
- IV
- 103.3%
- B/E move
- 4.8%
- Pseudo strike
- 29.32
- IV
- 124.2%
- B/E move
- 4.1%
75Δ
- Pseudo strike
- 22.71
- IV
- 95.9%
- B/E move
- 3.3%
- Pseudo strike
- 30.36
- IV
- 122.9%
- B/E move
- 2.9%
80Δ
- Pseudo strike
- 21.82
- IV
- 98.0%
- B/E move
- 2.4%
- Pseudo strike
- 32.61
- IV
- 133.7%
- B/E move
- 2.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 97.28% | |
| 87.98% | |
| 96.44% | |
| 94.08% | |
| 99.59% | |
| 109.09% | |
| 109.43% | |
| 114.01% | |
| 76.47% | |
| 80.79% | |
| 79.76% | |
| 78.25% | |
| 76.73% | |
| 76.12% | |
| 77.35% | |
| 78.96% | |
| 82.14% | |
| 76.28% | |
| 77.56% | |
| 80.83% | |
| 92.60% | |
| 94.72% | |
| 75.36% | |
| 79.45% | |
| 78.92% | |
| 83.81% | |
| 82.70% | |
| 82.31% | |
| 85.67% | |
| 95.41% | |
| 89.63% | |
| 98.59% | |
| 99.38% | |
| 107.36% | |
| 109.87% | |
| 121.17% | |
| 129.58% | |
| 150.65% | |
| 203.39% | |
| 83.59% | |
| 88.43% | |
| 88.41% | |
| 82.45% | |
| 86.91% | |
| 92.05% | |
| 89.80% | |
| 92.13% | |
| 84.05% | |
| 83.60% | |
| 87.58% |
Biotechnology
ANTX
Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.
More →ARCT
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
More →ARDX
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is…
More →ARGX
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The…
More →ARMP
Description unavailable
More →ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in…
More →